Top Companies in Cell Based Assays Market

The cell-based assays market is projected to reach USD 27.55 billion by 2030 from an estimated USD 17.84 billion in 2025, at a CAGR of 9.1% during the forecast period. Several key factors primarily drive the growth of the cell-based assays market. There is an increasing demand for drug discovery and development, along with a rising prevalence of cancer. Additionally, growing investments and funding for cell-based research play a significant role in the market's expansion.

The emphasis on personalized medicine and the strategic partnerships established to accelerate innovations in drug discovery also contribute to market growth. Furthermore, the adoption of artificial intelligence in drug discovery and cell analysis, alongside the expanding applications of cell-based assays in chronic diseases and personalized medicine, is expected to create further growth opportunities for the market in the coming years.

To know about the assumptions considered for the study download the pdf brochure

The global cell-based assays market is competitive with top players such as Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc. (US), Lonza (Switzerland), and Eurofins Scientific (Luxembourg). These market players have adopted strategies, such as new product launches, acquisitions, agreements, collaborations, and geographical expansions, to strengthen their position in the global cell-based assays market.

In March 2025, Beckman Coulter Life Sciences (US), a subsidiary of Danaher Corporation (US), launched the CytoFLEX mosaic Spectral Detection Module. This module offers high fluorescence sensitivity when connected to the CytoFLEX LX or S Flow Cytometers. The new module is available in two configurations: the CytoFLEX mosaic 88 for the CytoFLEX LX Flow Cytometer and the CytoFLEX mosaic 63 for the four-laser CytoFLEX S Flow Cytometer.

In January 2025, Merck KGaA (Germany) and Opentrons Labworks (US) entered into a multi-year agreement to automate assay kits on a custom Opentrons Flex workstation.

Danaher Corporation is a leading innovator in life sciences and diagnostics. It offers a wide range of products and services for medical, industrial, and commercial applications and has a robust presence in North America, Europe, Asia, and Latin America. The company also focuses on forming strategic alliances to strengthen its global footprint. For example, in October 2023, Danaher Corporation's Beckman Coulter Life Sciences partnered with 10x Genomics to enhance automation solutions for single-cell assay workflows. Additionally, Danaher is committed to expanding its facilities to grow its business. In May 2022, Cytiva announced the opening of a new manufacturing facility in Grens, Switzerland. This site will produce single-use kits for the Sepax and Sefia cell processing systems and consumables for the Xuri cell expansion systems.
Merck is a leading provider of solutions and services for research, biotechnology, and pharmaceutical drug development and production in the global life sciences industry. The company offers tools, services, and digital platforms to empower researchers in a wide range of fields. The company has a strong customer base across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa through a combination of direct sales teams, distributors, and wholesalers. Additionally, the company continues to focus on organic and inorganic growth strategies such as product launches, agreements, acquisitions, expansions, and collaborations.

Market Ranking

The cell-based assays (CBA) market is consolidated, with seven main players collectively holding 55–65% of the total market share. Danaher Corporation has a significant portion of this market, focusing on research and development investments to enhance its cell-based assay product offerings. Thermo Fisher Scientific Inc. excels in the market due to its broad product portfolio and strong global presence, which ensures accessibility worldwide. Merck KGaA maintains a notable market presence by adopting both organic and inorganic growth strategies, including product launches, agreements, collaborations, acquisitions, and expansions. BD has also made significant contributions to the CBA market through its successful product launches. Meanwhile, Agilent Technologies is expanding its cell-based assays business into new geographic regions through partnerships with local distributors.

The remaining 35–45% of the market is shared among other players. Market competition is driven by various factors, including technological advancements, cost-effectiveness, regulatory compliance, innovation in assay platforms, and the growing demand for personalized medicine and drug discovery.

Related Reports:

Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com